Treatment With Ranolazine in Microvascular Coronary Dysfunction (MCD): Impact on Angina Myocardial Ischemia

Trial Profile

Treatment With Ranolazine in Microvascular Coronary Dysfunction (MCD): Impact on Angina Myocardial Ischemia

Completed
Phase of Trial: Phase III

Latest Information Update: 22 Dec 2016

At a glance

  • Drugs Ranolazine (Primary)
  • Indications Angina pectoris
  • Focus Therapeutic Use
  • Acronyms RWISE
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 22 Dec 2016 Results of retrospective tissue tracking analysis assessing systolic/diastolic strain, using cardiac magnetic resonance imaging cine images acquired from RWISE trial (n=128) and healthy reference controls (n=43), published in the Clinical Cardiology.
    • 18 Oct 2016 Status changed from recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top